Image

Global Human Microbiome Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Healthcare
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Human Microbiome Market, By Product (Probiotics, Prebiotics, Medical Foods, Supplements, Others), Application (Therapeutics, Diagnostics), Disease Type (Obesity, Diabetes, Autoimmune Disorder, Metabolic and Gastrointestinal Disorders, Cancer, Other Diseases) – Industry Trends and Forecast to 2029.

Human Microbiome Market

Global Human Microbiome Market Analysis and Size

To improve the understanding of microbial flora pertaining to human health and various diseases, United States National Institute of Health (NIH) initiated a project named Human Microbiome Project in 2007. The first phase of this project was concerned with the identification of human microbiota and its characterisation.                           

  • Data Bridge Market Research analyses that the human microbiome market is expected to undergo a CAGR of 22.95% during the forecast period. This indicates that the market value, which was USD 599 million in 2021, would rocket up to USD 3,127.916 million by 2029. “Therapeutics” dominates the application segment of the human microbiome market owing to the increasing number of technological advancements and increase in funding for research and development into microbiome-based therapies worldwide. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Global Human Microbiome Market Definition

Human microbiomes refers to the aggregation of microorganisms that are present on and within the human body. Human microbiome is a full array of microorganisms such as bacteria, bacteriophage, fungi, protozoa and viruses. Factually humans have 10 times more of the microbial cells than human cells.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product (Probiotics, Prebiotics, Medical Foods, Supplements, Others), Application (Therapeutics, Diagnostics), Disease Type (Obesity, Diabetes, Autoimmune Disorder, Metabolic and Gastrointestinal Disorders, Cancer, Other Diseases)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

ENTEROME (France), Yakult (US), DuPont (US), Metabiomics Corporation (US), ViThera Pharmaceuticals, Inc. (US), Second Genome Inc. (US), MICROBIOME THERAPEUTICS LLC (US), Vedanta Biosciences, Inc. (US), Osel, Inc. (US), Merck Sharp & Dohme Corp (Germany), Seres Therapeutics (US), Synthetic Biologics, Inc. (US), Synlogic (US), 4D pharma plc (UK), Metabogen AB (Sweden), Ritter Pharmaceuticals (US), Symberix (US) and Symbiotix Biotherapies, Inc. (US)

Human Microbiome Market Dynamics

Drivers

  • The rise in the prevalence of diseases

Surging prevalence of respiratory diseases all around the globe is one of the major factors responsible for fostering growth in the market value. Also, increasing focus on the immunity development is all responsible for boosting the market growth rate.  

  • Research and development proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the medical instruments and devices will further create lucrative market growth opportunities. Research and development proficiencies being conducted for the development of drugs is also bolstering the market growth rate.

  • Government investments on healthcare infrastructure

The increase in the funding by the federal government is set to drive the market growth rate. Moreover, growth and expansion of healthcare industry being driven by both public and private players especially in the developing economies will create lucrative market growth opportunities. Also, high return on investments assured by the research activities will also work in the favour of the market.

Additionally, surge in investment by biotechnology and biopharmaceutical industries, surge in the personal disposable income level, introduction of technologically driven products in hospitals, increasing investment for the development of advanced medical products and devices and rise in the popularity of minimally invasive surgeries, positively affect the market growth rate.

Opportunities

Furthermore, upsurge in the public-private funding for target research activities, growing geriatric population base and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2022 to 2029. Additionally, surging number of strategic collaborations, rising internet penetration rate, growing number of hospitals and laboratories, growing focus on human microbiome therapeutics development and increasing per capita expenditure on health care will further expand the market's growth rate in the future. 

Restraints/Challenges Global Human Microbiome Market

On the other hand, high cost associated with the research and development proficiencies, limited infrastructural facilities and inadequate research on the human microbiome are expected to obstruct market growth. Also, lack of favourable reimbursement scenario and technology penetration in the developing economies, barriers in proving the causal link between dysbiosis and diseases, and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2022-2029.

This human microbiome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the human microbiome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Human Microbiome Market

COVID-19 has had a limited impact on the market. Rising interest of researchers on human microbiomes owing to its association with several respiratory diseases and immunity has been working in the favour of the market. Pandemic led to putting a halt on many research and development activities which also resulted in affecting this market. Rising number of relaxation would therefore, prove to be beneficial for the market. For example- in July 2021, Seres Therapeutics, Inc. entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, in the United States and Canada. The aim of this Investigational Microbiome Therapeutic is to lead the way for entirely new treatment modality.?

Recent Development

  • In September 2021, PhenoBiome today launched a human gut microbiome assay through Genetic Direction, which will process the assays in its CLIA- and CAP-certified laboratory.
  • In June 2021, NovoBiome, a drug discovery company has notified that they are building NovoSift, a disruptive ex-vivo research and discovery platform which will analyze the symbiotic relationship between the microbiota and the human intestine.

Global Human Microbiome Market Scope

The human microbiome market is segmented on the basis of product, application and disease type. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • Probiotics
  • Prebiotics
  • Medical Foods
  • Supplements
  • Others

On the basis of product, the human microbiome market in is segmented into probiotics, prebiotics, medical foods, supplements and others.

Application

  • Therapeutics
  • Diagnostics

On the basis of application, the human microbiome market in is segmented into therapeutics and diagnostics.

Disease Type

  • Obesity
  • Diabetes
  • Autoimmune Disorder
  • Metabolic and Gastrointestinal Disorders
  • Cancer
  • Other Diseases

On the basis of disease type, the human microbiome market in is segmented into obesity, diabetes, autoimmune disorder, metabolic and gastrointestinal disorders, cancer and other diseases.

Human Microbiome Market Regional Analysis/Insights

The human microbiome market is analysed and market size insights and trends are provided by country, product, application and disease type as referenced above.

The countries covered in the human microbiome market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the human microbiome market because of the strong base of healthcare facilities, rising investment from key players in the growth of the advanced devices, growing number of processes pertaining to drug development, and rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, rise in the incidences of lifestyle-related diseases and autoimmune disorders and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The human microbiome market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for human microbiome market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the human microbiome market. The data is available for historic period 2010-2020.

Competitive Landscape and Human Microbiome Market Share Analysis

The human microbiome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to human microbiome market.

Some of the major players operating in the human microbiome market are ENTEROME (France), Yakult (US), DuPont (US), Metabiomics Corporation (US), ViThera Pharmaceuticals, Inc. (US), Second Genome Inc. (US), MICROBIOME THERAPEUTICS LLC (US), Vedanta Biosciences, Inc. (US), Osel, Inc. (US), Merck Sharp & Dohme Corp (Germany), Seres Therapeutics (US), Synthetic Biologics, Inc. (US), Synlogic (US), 4D pharma plc (UK), Metabogen AB (Sweden), Ritter Pharmaceuticals (US), Symberix (US) and Symbiotix Biotherapies, Inc. (US) among others.

Research Methodology : Global Human Microbiome Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-human-microbiome-market


SKU-

Why Choose Us


Frequently Asked Questions

The Human Microbiome Market will be projected USD 3,127.916 million during the forecast period of 2022 to 2029.
The Human Microbiome Market is Projected to Grow at a CAGR of 22.95% During the Forecast Period of 2022 to 2029.
Factors such as the Increasing Prevalence of Lifestyle Related Disorders, Increasing Number of Research and Development Activities, rising Geriatric Population Base and Increasing Personal Disposable Income are the Major Growth Driving Factors for Human Microbiome Market.
ENTEROME (France), Yakult (US), DuPont (US), Metabiomics Corporation (US), ViThera Pharmaceuticals, Inc. (US), Second Genome Inc. (US), MICROBIOME THERAPEUTICS LLC (US), Vedanta Biosciences, Inc. (US), Osel, Inc. (US), Merck Sharp & Dohme Corp (Germany), Seres Therapeutics (US), Synthetic Biologics, Inc. (US), Synlogic (US), 4D pharma plc (UK), Metabogen AB (Sweden), Ritter Pharmaceuticals (US), Symberix (US) and Symbiotix Biotherapies, Inc. (US) are the major companies operating in Human Microbiome Market.
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America are Covered in the Human Microbiome Market.